trending Market Intelligence /marketintelligence/en/news-insights/trending/v-1BCtOKcG-gsAt8LWMA0Q2 content esgSubNav
In This List

Helix BioPharma, ProMab to collaborate on cell-based therapies

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


Helix BioPharma, ProMab to collaborate on cell-based therapies

Helix Biopharma Corp. will collaborate with ProMab Biotechnologies Inc. to develop cell-based therapies.

Under a nonbinding letter of intent, the companies will complete a due diligence and establish a collaboration to develop chimeric antigen receptor T cell therapy for hematological malignancies and solid tumors.